Vistagen (VTGN) announced that the last patient has completed the randomized, double-blind, placebo-controlled portion of the PALISADE-3 Phase 3 clinical trial evaluating fasedienol for the acute treatment of social anxiety disorder. The open label extension of the study is currently ongoing.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VTGN:
- Analysts Predict Up to 550% Rally for These 2 ‘Strong Buy’ Penny Stocks
- VistaGen Therapeutics Appoints Paul R. Edick to Board
- Vistagen’s Phase 3 Trial: A Potential Game-Changer for Anxiety Treatment?
- Vistagen’s Phase 3 Trial of Fasedienol Nasal Spray: A Potential Game-Changer for Anxiety Treatment
- Vistagen’s Promising Phase 2 Trial for Anxiety Treatment: A Market Game Changer?